Studieoverzicht
Study name: OMIT IO
Histology | NSCLC | ||
---|---|---|---|
Tumor stage | Stage III - IV | ||
Host / recruiting site 1 | LUMC | Enrollment | Recruiting |
Host / recruiting site 2 | Radboud UMC | Enrollment | Recruiting |
Therapy line | First line (1L) | ||
Design |
Prospectieve, gerandomiseerde fase II multicenter studie |
||
Intervention | Chemotherapie alleen versus chemo-immunotherapie |
||
Key outcome parameters | Effectiviteit van alleen chemotherapie versus chemo-immunotherapie, primaire uitkomst ORR. Secundaire uitkomst PFS en OS |
||
Key inclusion criteria |
|
||
Key exclusion criteria | Symptomatische CNS metastasen met noodzaak voor directe lokale behandeling |
||
Contact information | Log in voor de contactinformatie |